Optiburn
Optiburn, licence 80080958: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Other names
- Optiburn Amped
- Licence holder
- Platinum Labs Global LLC
- NPN or DIN-HM
- 80080958
- Status
- Active licence
- Licence date
- 31 October 2017
- Revision date
- 18 May 2018
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Sel interne de (2R)-2-(Acétyloxy)-3-carboxy-N,N,N-triméthyl-1-propanaminium Source : Acétyl-L-Carnitine | 250.0 mg | Not calculated |
| Nelumbo nucifera Source : Feuille Extract : Matériel brut frais Extraction ratio : 10:1 Dry plant equivalent : 1500 mg | 150.0 mg | Not calculated |
| 3,7-dihydro-1,3,7-triméthyl-1H-purine-2,6-dione Source : Caféine | 125.0 mg | Not calculated |
| Taraxacum officinale Source : Racine Extract : Matériel brut frais Extraction ratio : 4:1 Dry plant equivalent : 400 mg | 100.0 mg | Not calculated |
| (+-)-1,2,3,4-Tétrahydro-1-[(4-hydroxyphényl)méthyl]-6,7-isoquinolinediol Source : Chlorhydrate d'higénamine | 25.0 mg | Not calculated |
| 4-hydroxy-alpha-[(méthylamino)méthyl]benzèneméthanol Source : Synephrine hydrochloride | 15.0 mg | Not calculated |
Non-medicinal ingredients
Stéarate de magnésium, farine de riz, Gélatine
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes de sexe masculin | minimum: 18.0 Année(s) ; maximum: 40.0 Année(s) | 1.0 Capsule | 1.0 Tous les jours |
Uses authorised in Canada
Workout supplement. Athletic support. Helps (temporarily) to relieve fatigue, to promote endurance, and to enhance motor performance.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Ensure to drink enough fluid before, during and after exercise. If you are pregnant or breastfeeding, consult a healthcare practitioner before using this product. Do not use if you have cardiovascular disease risk factors (e.g. high blood pressure, high cholesterol, obesity), a seizure disorder or glaucoma. Consult a health care practitioner prior to use if you are taking lithium. Consult a health care practitioner prior to use if you have prostate disorders. Consumption with caffeine-containing products is not recommended as it may increase the risk of adverse effects. Do not consume if you are taking decongestant-containing cold preparations (i.e. phenylephrine or pseuodoephedrine), products containing ephedra or ephedrine, or other medications which increase blood pressure. May cause digestive problems. Caffeine has been shown to reduce blood flow to the heart muscle during exercise which might lead to cardiovascular complications such as chest pain, and irregular heartbeat even in healthy individuals. If those symptoms occur discontinue use and consult a health care practitioner. This product is not intended as a substitute for sleep. Hypersensitivity/allergy is known to occur, in which case, discontinue use. If you have heart disease, high or low blood pressure, kidney or liver disorder, diabetes or edema or are taking products containing diuretics, do not use. Stop use and seek medical attention immediately if you experience insomnia, restlessness, dizziness and/or tremor, nausea, loss of appetite, disturbance of urination, confusion, muscle weakness or pain, abnormal heart beat, severe headache, and/or difficulty breathing. If you have gall bladder disease, and/or intestinal obstruction, consult a health care practitioner prior to use. Consult a health care practitioner prior to use if you are taking prescription medication. Consumption with natural health products (e.g. bitter orange extract, synephrine, octopamine, ephedra) or other drugs (e.g. ephedrine) which increase blood pressure is not recommended. Consult a healthcare practitioner prior to use if you have detrusor instability (overactive bladder syndrome). Consult a healthcare practitioner prior to use if you are taking medications and/or natural health products for allergy symptoms, asthma, cough/cold, and weight control. Consult a healthcare practitioner prior to use if you are taking other products which contain phenylpropanolamine. Consults a health care practitioner prior to use if you have difficulty urinating due to prostate enlargement, pre-existing psychiatric conditions and thyroid problems. Keep out of reach of children. Do not use if you have taken monoamine oxidase (MOA) inhibitors in the past 2 weeks.
Source
Official Health Canada record, licence 80080958
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2018. Photograph the packaging to check whether it has changed.
Has the product changed? Photograph the packaging.